Bay Street News

GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

March 16, 2020
- NASDAQ Companies
  0
ShareTweet

Bay Street News

ShareTweet
» View More News for March 16, 2020

Tweets by baystnews

© 2020 BayStNews.com - All Rights Reserved
  • Home
  • TSX News
  • TSX Venture News
  • NASDAQ Companies
  • NYSE Companies
  • Canadian Stock Exchange News
  • Pink Sheets News
  • OTCBB News
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search